Loading market data...
Sun, 06 Sept 2026
08:00:38 pm
Sun, 06 Sept 2026
08:00:38 pm
Synopsis
Immuneel Therapeutics raised over ₹100 crore in Series B funding to expand Qartemi, India's pioneering CAR-T cancer therapy, manufacturing capacity, R&D, and international operations.
Cancer-focused biotech startup Immuneel Therapeutics has secured over ₹100 crore in fresh Series B funding to accelerate the commercialization of its CAR-T therapy platform, expand manufacturing capacity, and strengthen its global presence. The funding marks a significant milestone for India's rapidly evolving cell and gene therapy sector and highlights growing investor confidence in advanced cancer treatment technologies.
| Particulars | Details |
|---|---|
| Company | Immuneel Therapeutics |
| Funding Round | Series B |
| Amount Raised | ₹100+ Crore |
| USD Equivalent | Approximately $10.5 Million |
| Headquarters | Bengaluru |
| Sector | Biotechnology & Cell Therapy |
| Lead Investors | Singularity AMC, Rainmatter |
| Existing Investors Participating | Kiran Mazumdar-Shaw, Eight Roads Ventures, F-Prime Capital |
| Founded | 2018 |
India's biotechnology sector received a major boost after Immuneel Therapeutics announced a fresh capital raise of more than ₹100 crore in a Series B funding round.
The Bengaluru-based company is among India's leading cell and gene therapy innovators and has emerged as a key player in developing advanced immunotherapy treatments for cancer patients. The latest funding round attracted a combination of new institutional investors and existing backers, reflecting continued confidence in the company's long-term growth strategy and technological capabilities.
The fundraising comes at a time when global interest in personalized cancer treatments, immunotherapy platforms, and cell-based therapies continues to rise rapidly.
| Investor Category | Participants |
|---|---|
| New Investors | Singularity AMC, Rainmatter by Zerodha |
| Existing Investors | Kiran Mazumdar-Shaw, Eight Roads Ventures, F-Prime Capital |
| Additional Participants | High-Net-Worth Individuals |
| Strategic Area | Planned Utilization |
|---|---|
| GMP Manufacturing Expansion | High Priority |
| Commercialization of Qartemi | High Priority |
| Research & Development | Significant |
| International Expansion | Strategic Focus |
| Pipeline Development | Ongoing |
Management indicated that the proceeds will primarily be deployed to scale manufacturing capabilities, strengthen commercialization efforts, and expand the company's research pipeline.
Unlike traditional pharmaceutical businesses that manufacture chemical drugs at scale, CAR-T therapies require highly specialized facilities, sophisticated manufacturing processes, and stringent quality control systems.
Scaling such operations is capital intensive.
| Requirement | Importance |
|---|---|
| GMP Facilities | Critical |
| Clinical Development | High |
| Regulatory Compliance | Essential |
| Manufacturing Infrastructure | Critical |
| Research Pipeline | High |
| International Expansion | Strategic |
The latest funding provides Immuneel with the financial resources required to strengthen these capabilities and expand treatment access to more patients.
CAR-T (Chimeric Antigen Receptor T-cell) therapy is one of the most advanced forms of cancer immunotherapy currently available.
Instead of using conventional chemotherapy or radiation, CAR-T therapy modifies a patient's own immune cells to identify and destroy cancer cells.
| Step | Process |
|---|---|
| 1 | Patient's T-cells are collected |
| 2 | Cells are genetically modified |
| 3 | Modified cells are expanded in laboratory facilities |
| 4 | Enhanced immune cells are reinfused into the patient |
| 5 | Modified cells target and attack cancer |
This personalized treatment approach has shown promising outcomes in certain blood cancers, particularly in patients who have exhausted conventional treatment options.
One of the biggest drivers behind investor interest in Immuneel is Qartemi, the company's flagship CAR-T therapy.
| Parameter | Details |
|---|---|
| Product | Qartemi |
| Therapy Type | CAR-T Cell Therapy |
| Indication | B-Cell Non-Hodgkin Lymphoma |
| Market Position | Globally Benchmarked Indian CAR-T Therapy |
| Commercial Status | Commercialized |
Qartemi was developed to address a major gap in access to advanced cancer treatments in India. International CAR-T therapies often cost several crores per patient, placing them beyond the reach of most individuals.
Immuneel's objective has been to make such therapies more accessible while maintaining global-quality standards.
India's cancer burden continues to rise steadily, creating a significant demand for innovative treatment options.
| Growth Driver | Impact |
|---|---|
| Rising Cancer Incidence | High |
| Precision Medicine Adoption | Growing |
| Biotechnology Innovation | Strong |
| Healthcare Infrastructure Expansion | Positive |
| Medical Tourism Potential | Significant |
| Government Focus on Innovation | Supportive |
The country is increasingly positioning itself as a hub for advanced biologics, personalized medicine, and cell-based therapies.
A notable aspect of the funding announcement is Immuneel's focus on expanding beyond India.
| Region | Strategic Importance |
|---|---|
| Asia-Pacific | High Growth Market |
| Middle East | Expanding Healthcare Spending |
| Southeast Asia | Clinical Partnership Opportunities |
| Australia | Advanced Research Ecosystem |
The company is already pursuing collaborative opportunities across international markets to broaden access to advanced cancer therapies.
Beyond Qartemi, Immuneel is building a broader pipeline of cell and gene therapies targeting various hematological cancers and immune-related conditions.
| Focus Area | Status |
|---|---|
| CD19 CAR-T Programs | Commercial Stage |
| Multiple Myeloma Therapies | Clinical Development |
| Next-Generation Cell Therapies | Research Stage |
| Personalized Immunotherapy | Ongoing Development |
Clinical research efforts continue to strengthen the company's long-term growth potential.
The latest fundraising also reflects a broader trend within India's healthcare innovation ecosystem.
Over the past decade, the country has witnessed increasing investment in:
| Theme | Growth Potential |
|---|---|
| Cell Therapy | Very High |
| Gene Therapy | Very High |
| Precision Medicine | High |
| Oncology Innovation | High |
| Biologics Manufacturing | High |
Investors increasingly view these areas as long-term growth opportunities capable of transforming healthcare outcomes.
| Competitive Factor | Strength |
|---|---|
| Indigenous Manufacturing | Strong |
| Specialized Cell Therapy Expertise | High |
| Experienced Founding Team | Strong |
| Strategic Investors | Strong |
| Commercialized Product | Significant |
| International Expansion Potential | Growing |
The company's combination of scientific expertise, manufacturing capability, and strategic backing creates a meaningful competitive position within India's biotechnology landscape.
| Positive Factors |
|---|
| Growing Cancer Treatment Demand |
| Commercialized CAR-T Platform |
| Strong Investor Backing |
| International Expansion Plans |
| Advanced Manufacturing Capabilities |
| Expanding Pipeline |
| Risk Factors |
|---|
| Regulatory Complexity |
| Long Clinical Development Cycles |
| High Manufacturing Costs |
| Competitive Global Landscape |
| Reimbursement Challenges |
| Scaling Risks |
The global CAR-T therapy market is expected to witness substantial growth over the coming decade as healthcare systems increasingly adopt personalized and cell-based treatments.
For India, the emergence of companies such as Immuneel represents a critical step toward reducing dependence on imported therapies while improving patient access to advanced cancer treatments.
As manufacturing scales and costs gradually decline, CAR-T therapies could become increasingly accessible to a larger patient population.
Immuneel Therapeutics' ₹100 crore Series B funding round represents more than just a capital raise. It highlights the growing maturity of India's biotechnology ecosystem and the increasing investor appetite for next-generation healthcare innovation.
The successful commercialization of Qartemi has provided the company with a meaningful foundation upon which to build a broader cell and gene therapy platform. Combined with fresh capital, strong investor backing, and expanding international ambitions, Immuneel appears well positioned to play a significant role in the future of cancer treatment across India and emerging global markets.
For India's healthcare and biotechnology sectors, the funding serves as another signal that advanced therapeutics, precision medicine, and personalized cancer treatments are moving from experimental concepts toward commercial reality.
Immuneel Therapeutics is a Bengaluru-based biotechnology company focused on developing and commercializing cell and gene therapies for cancer treatment. Founded in 2018, the company aims to make advanced immunotherapy treatments accessible and affordable for patients in India and beyond.
| Particulars | Details |
|---|---|
| Company Name | Immuneel Therapeutics |
| Founded | 2018 |
| Headquarters | Bengaluru |
| Industry | Biotechnology |
| Core Focus | Cell & Gene Therapy |
| Flagship Product | Qartemi |
| Key Therapeutic Area | Oncology |
| Business Model | Advanced Cancer Therapeutics |
| Founder |
|---|
| Kiran Mazumdar-Shaw |
| Siddhartha Mukherjee |
| Kush Parwar |
Immuneel Therapeutics raised over ₹100 crore (approximately $10.5 million).
The round included Singularity AMC, Rainmatter by Zerodha, Kiran Mazumdar-Shaw, Eight Roads Ventures, and F-Prime Capital.
Qartemi is Immuneel's CAR-T cell therapy designed for certain blood cancers.
CAR-T therapy is a personalized cancer treatment that modifies a patient's immune cells to attack cancer.
The company is headquartered in Bengaluru, India.
The funds will support manufacturing expansion, commercialization, R&D, and international growth.
The company plans expansion across Asia-Pacific and the Middle East.
The funding strengthens India's position in advanced biotechnology and cancer treatment innovation.
Financial journalist specializing in market analysis, stock research, and investment trends. Dedicated to providing accurate, timely insights for informed decision-making.
Credentials: Experienced financial journalist with expertise in equity markets and economic analysis
The information provided in this article is for educational and informational purposes only and should not be construed as financial, investment, or legal advice. welomoney does not provide personalized investment recommendations.
For detailed terms and conditions, please read our Disclaimer and Terms of Service.
No additional articles in this category yet.
